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Abstract
The epidermal growth factor receptor (EGFR), which regulates cell growth and survival, is integral to colon tumorigenesis.
Lipid rafts play a role in regulating EGFR signaling, and docosahexaenoic acid (DHA) is known to perturb membrane domain
organization through changes in lipid rafts. Therefore, we investigated the mechanistic link between EGFR function and
DHA. Membrane incorporation of DHA into immortalized colonocytes altered the lateral organization of EGFR. DHA
additionally increased EGFR phosphorylation but paradoxically suppressed downstream signaling. Assessment of the EGFR-
Ras-ERK1/2 signaling cascade identified Ras GTP binding as the locus of the DHA-induced disruption of signal transduction.
DHA also antagonized EGFR signaling capacity by increasing receptor internalization and degradation. DHA suppressed cell
proliferation in an EGFR-dependent manner, but cell proliferation could be partially rescued by expression of constitutively
active Ras. Feeding chronically-inflamed, carcinogen-injected C57BL/6 mice a fish oil containing diet enriched in DHA
recapitulated the effects on the EGFR signaling axis observed in cell culture and additionally suppressed tumor formation.
We conclude that DHA-induced alteration in both the lateral and subcellular localization of EGFR culminates in the
suppression of EGFR downstream signal transduction, which has implications for the molecular basis of colon cancer
prevention by DHA.
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Introduction
The epidermal growth factor receptor (EGFR;ErbB1) is a
transmembrane receptor tyrosine kinase, which contains an
extracellular binding domain, a single transmembrane spanning
domain, and a cytoplasmic tyrosine kinase domain [1,2]. Ligands
for EGFR, including EGF, bind to the extracellular domain of
EGFR, stimulating conformational changes that support receptor
dimerization. Receptor dimerization results in the activation of
the intracellular tyrosine kinase domain, which phosphorylates
the dimerization partner on specific tyrosine residues. The
phosphorylated tyrosine residues then function as docking sites
for adaptor proteins, which serve to activate intracellular
signaling cascades. Ultimately, these cascades result in alterations
of gene expression, which determines the biological response to
receptor activation.
Key to the ability of EGFR to activate downstream pathways is
its localization in lipid raft domains of the plasma membrane
[3,4,5,6,7]. Lipid rafts are highly-ordered, detergent-resistant
membrane domains enriched in cholesterol, sphingolipids, and
saturated fatty acyl chains that function as signaling platforms [8].
Localization of EGFR to lipid rafts is crucial for efficient EGFR
signaling, partially due to colocalization with downstream
mediators within lipid rafts [9,10]. In addition, disruption of lipid
rafts results in the relocalization of EGFR to bulk membrane
regions, which alters EGFR activation and signaling
[5,6,9,11,12,13]. Therefore, it is likely that these specialized
membrane domains provide a mechanism for spatial and temporal
control of EGFR signaling.
Aberrant expression or activation of EGFR has been strongly
linked to the etiology of several human epithelial cancers,
including colon cancer [14]. Colon cancer is a major public
health concern, being the third leading cause of cancer related
deaths in the United States [15]. Signaling through EGFR
activates various cellular processes involved in carcinogenesis, such
as cell proliferation, inhibition of apoptosis, angiogenesis, cell
motility, and metastasis [16,17]. The numerous signaling cascades
that radiate from EGFR, including the Akt, extracellular signal
regulated kinase (ERK) 1/2, and signal transducer and activator of
transcription (STAT) 3 pathways, mediate a variety of mitogenic,
metastatic, and other tumor-promoting cellular activities. Signal-
ing through EGFR is up-regulated in colon cancer [18], and
inhibition of signaling through EGFR has been shown to prevent
colon tumor formation [19]. Additionally, overexpression of
EGFR has been reported in up to 85% of human colon cancers
[20,21,22,23,24], and expression of EGFR in colon cancer is
correlated with a more aggressive disease and poor patient
prognosis [25,26,27,28]. Collectively, these data implicate EGFR
as a master signal capable of driving colon tumorigenesis. For
these reasons, EGFR is an attractive target for therapeutic
intervention; thus, intense efforts have been made to inhibit the
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activity of EGFR by designing small molecules against the tyrosine
kinase domain (erlotinib, gefitinib, and lapatinib) or antibodies
against the ligand binding domains (cetuximab and panitumumab)
[29,30].
Importantly, there is substantial experimental, epidemiological,
and clinical evidence suggesting that consumption of n-3
polyunsaturated fatty acids (PUFA), including docosahexaenoic
acid (DHA, 22:6D4,7,10,13,16,19) and eicosapentaenoic acid (EPA,
20:5D5,8,11,14,17) is protective against colon tumorigenesis
[31,32,33,34,35,36,37,38,39,40,41,42,43,44,45]. However, the
exact mechanisms by which n-3 PUFA function as chemopre-
ventive agents have not been fully elucidated. Recent evidence
suggests that perturbation of cell signaling events emanating from
lipid rafts could be one mechanism of action of n-3 PUFA,
specifically DHA [46,47,48]. DHA can profoundly influence
cellular membrane composition and has been shown to have
significant effects on plasma membrane properties, including
membrane fluidity, phase behavior, permeability, fusion, flip-flop,
and protein function following incorporation into membrane
phospholipids [48,49]. Due to its high level of unsaturation,
DHA has very poor affinity for cholesterol, which is enriched in
lipid raft regions of the plasma membrane [50]. Studies
conducted in various cell types have shown that treatment with
DHA can alter the size of lipid rafts as well as signaling that is
known to occur within rafts [47,51,52,53]. Furthermore,
evidence suggests that treatment of cells with DHA results in
exclusion of certain proteins from lipid rafts causing disruption of
signal transduction events [46]. Therefore, we hypothesized that
DHA exerts its effect on colon cancer in part by altering the
localization and signaling of EGFR.
Two initial studies have assessed the effects of n-3 PUFA on
EGFR localization and signaling. Initially, a combination of EPA
and DHA was shown to alter the localization of EGFR within the
plasma membrane of a breast cancer cell line. The altered
localization was concurrent with increased ligand-induced EGFR
phosphorylation and downstream activation of p38MAPK [54].
The second study utilized DHA alone, and similarly reported an
alteration in EGFR localization in lung and breast cancer cell lines
[55]. Although EGFR phosphorylation and downstream signaling
was only investigated under basal conditions, the increase in
EGFR phosphorylation was associated with a suppression of Ras
and ERK1/2 activation upon DHA treatment. This observation,
although intriguing, did not directly address how n-3 PUFA
impact EGFR functionality since receptor activation was never
examined within the context of a ligand specific for the EGFR.
Therefore, it is ambiguous whether the suppressive effects
observed are due to alterations in EGFR or other parallel
signaling pathways. Additionally, these studies only assessed a
single downstream cascade from EGFR. Consequently, we set out
to clarify the precise effect of n-3 PUFA on EGFR signaling in the
colon.
In this study, we demonstrate that treatment with DHA alters
the localization of EGFR within the plasma membrane.
Additionally, DHA induces an increase in ligand-induced EGFR
phosphorylation with a paradoxical decrease in downstream
signaling. These results reveal a novel mechanism by which
DHA suppresses cell signaling by perturbing localization of key
signaling mediators within lipid rafts. The suppressive effect on
EGFR signaling is enhanced by DHA-induced increases in EGFR
internalization and degradation. Furthermore, our data demon-
strate an uncoupling of receptor phosphorylation from down-
stream signaling that may affect our understanding of membrane
localized receptor-mediated signaling events.
Results
DHA Reduces Partitioning of EGFR into Lipid Raft
Domains
Lateral organization of EGFR within the plasma membrane is
directly linked to receptor function. Previous reports have shown
that n-3 PUFA can alter the localization of EGFR within the
plasma membrane of lung and breast cancer cells [54,55].
Therefore, we first determined the effect of DHA on localization
of EGFR within the plasma membrane of colonocytes. Initial
experiments were conducted using the immortalized Young Adult
Mouse Colonocyte (YAMC) cell line, originally described by
Whitehead and colleagues [56]. We employed two complemen-
tary, established methods to investigate the localization of EGFR.
First, a detergent-free method of plasma membrane fractionation
to isolate lipid raft enriched domains was utilized [57]. We chose
to use a detergent-free method due to strong evidence suggesting
that detergent-based methods of extraction can lead to artifacts
[58]. Cells were either untreated (control; no fatty acid) or
incubated with 50 mM DHA or linoleic acid (LA, 18:2n26;
control fatty acid) for 72 h. For the final 16–18 h of fatty acid
treatment, cells were incubated in low serum media (0.5% FBS)
prior to harvesting because EGFR has been shown to be localized
to lipid rafts prior to activation. The bulk plasma membrane was
isolated and fractionated on density gradients into three fractions,
and each fraction was analyzed using Western blotting. The lowest
density fraction from each treatment was enriched with caveolin
and GM-1, which served as lipid raft markers, and depleted of
clathrin, which is excluded from lipid rafts, indicating that this
fraction is enriched with lipid rafts. In control and LA treated cells,
the majority of EGFR was concentrated in the lipid raft enriched
fraction of the plasma membrane (Figure 1A). However, in DHA
treated cells, EGFR displayed a more even distribution across all
plasma membrane fractions, indicating a lateral reorganization of
EGFR. Additionally, confocal fluorescence microscopy was used
to determine localization of EGFR. Control and fatty acid treated
cells were co-transfected with monomeric GFP-tagged EGFR
(EGFR-mGFP) and RFP-tagged truncated H-Ras (RFP-tH). RFP-
tH, which is targeted by a CAAX motif that is both palmitoylated
and farnesylated, is a well-established lipid raft marker that is
localized exclusively to low density fractions on sucrose gradients
[59,60]. In control and LA treated cells, plasma membrane
EGFR-mGFP strongly colocalized with RFP-tH (Figure 1B). This
colocalization was significantly decreased by treatment with DHA.
Interestingly, in many of the DHA treated cells, EGFR-mGFP and
RFP-tH formed patches that were localized in close proximity, but
not overlapping. The overall localization of the lipid raft marker,
RFP-tH, was altered by treatment with DHA, which is in
agreement with a plethora of data suggesting that DHA alters
lipid rafts [51–53]. Additionally, a large portion of EGFR in the
DHA-treated cells was localized intracellularly. These comple-
mentary datasets indicate that DHA treatment altered the plasma
membrane organization of EGFR within colonocytes, which is
consistent with previous observations in breast and lung cells
[54,55].
DHA Suppresses EGFR Signaling but Increases EGFR
Phosphorylation
Due to the role that lipid rafts play in the regulation of EGFR
activation and downstream signaling, we next investigated the
effects of DHA on EGFR activation status and signaling in
YAMC cells. Untreated and fatty acid treated cells were
incubated in low serum media (0.5% FBS) overnight in order
to reduce signaling from growth factors within the serum.
Regulation of EGFR Signal Transduction
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Figure 1. DHA reduces localization of EGFR to lipid rafts. A) YAMC cells were untreated (control) or treated with 50 mM BSA-complexed fatty
acids (LA or DHA) for 72 h (12 flasks per treatment). For the final 16–18 h, cells were incubated with low serum media (0.5% FBS) with the same
concentration of fatty acids. Cells were harvested from each flask, pooled (n = 12), and the plasma membrane (PM) was isolated. Following isolation,
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Subsequently, cells were stimulated with 25 ng/mL EGF for
10 min followed by isolation of cell lysates. To assess the effects
of fatty acid treatment on EGF-induced EGFR phosphorylation,
lysates were probed for EGFR phosphorylated on Tyr1068, one
of the major sites of EGFR phosphorylation that is involved in
activation of downstream signaling. DHA treatment resulted in a
greater than two-fold increase in EGFR phosphorylation
compared to untreated control or LA treated cells (Figure 2A).
EGFR was also immunoprecipitated from cell lysates followed by
immunoblotting for total phosphorylated tyrosine residues.
Consistent with the initial results, DHA enhanced total EGFR
tyrosine phosphorylation by greater than two-fold (Figure 2A).
Since EGFR phosphorylation is characteristically associated with
activation of downstream signaling, we further probed cell lysates
for phosphorylation of downstream effector proteins, including
ERK1/2, STAT3, and Akt. DHA treatment resulted in a ,50%
reduction in the activation of ERK1/2 and STAT3 in DHA
treated cells compared to untreated control and LA treated cells
(Figure 2B). DHA had no effect on Akt phosphorylation at
Ser473 (Figure 2B). The mammalian target of rapamycin
(mTOR) is a serine/threonine kinase that is often hyperactivated
in cancer, and stimulation of both Akt and ERK1/2 can lead to
activation of a protein complex containing mTOR, i.e.,
mTORC1. To assess mTORC1 activity, we measured phos-
phorylation of ribosomal S6 kinase (S6K), a kinase that is directly
phosphorylated by mTOR at Thr389. We found that DHA
significantly suppressed EGF-induced phosphorylation of S6K,
indicating reduced activation of mTOR (Figure 1C). Together,
these data suggest that DHA disrupts the EGFR signaling
cascade in colonocytes by disengaging EGFR phosphorylation
from signal transduction.
We also investigated the effect of DHA on EGFR phosphor-
ylation and signaling at multiple time points. Untreated control
and DHA treated cells were stimulated with 25 ng/mL EGF
from 0–30 min. Consistent with initial results, EGFR phosphor-
ylation was significantly increased by DHA treatment at 2, 5,
and 10 min following stimulation (Figure 3A). EGFR phosphor-
ylation peaked in DHA treated cells at 5 min and started
decreasing, whereas EGFR phosphorylation was highest at
10 min in control samples, suggesting a dynamic alteration in
EGFR regulation. Downstream signaling from EGFR through
ERK1/2 and STAT3 was suppressed by DHA at each time
point assessed (Figure 3B,C).
Effect of Fatty Acid on EGFR is DHA Specific
Since DHA and EPA are both long chain omega-3 fatty acids
that have been shown to reduce colon tumor development, we
examined whether each of these fatty acids cause an increase in
EGFR phosphorylation or if the effect is specific to DHA. We also
assessed the effects of arachidonic acid (AA; 20:4 n26) on EGFR
activation as a control, long-chain n-6 PUFA. Lysates were probed
for phosphorylated EGFR. Neither AA nor EPA treatment
resulted in an increase in EGFR phosphorylation compared to
control (Figure 3D). Only DHA treatment increased the
phosphorylation status of EGFR.
Mechanism of DHA-induced Increase in EGFR
Phosphorylation
EGFR phosphorylation is controlled by a variety of factors.
Therefore, we next determined the mechanism by which DHA
increases EGFR phosphorylation. Previous studies have suggested
a number of possible contributing mechanisms. For example,
EGFR phosphorylation has been shown to be increased by an
adaptive mechanism in response to suppression of downstream
signaling through ERK1/2 [61]. Another study demonstrated that
the lipid environment directly influences EGFR dimerization,
which results in increased EGFR phosphorylation [62]. Since we
demonstrated that DHA both alters the membrane environment
of EGFR and suppresses ERK1/2 phosphorylation, we next
assessed whether either of these two mechanisms contributed to
the observed DHA-induced increase in EGFR phosphorylation.
First, we utilized a specific inhibitor of ERK1/2, U0126, to
recapitulate the suppressive effect of DHA on ERK1/2 activation.
We then assessed the effect of this inhibitor on EGFR activation
status. We found that treatment of cells with 10 mMU0126 for 2 h
prior to stimulation completely inhibited EGF-induced activation
of ERK1/2 (Figure 4A). However, this inhibition had no effect on
overall EGFR phosphorylation, suggesting that a downstream
feedback-mediated increase in EGFR phosphorylation induced by
ERK1/2 suppression is not a mechanism by which DHA
enhances EGFR phosphorylation.
We subsequently measured the effect of DHA on EGFR
dimerization. Following stimulation with EGF, EGFR dimers were
linked using bis[sulfosuccinimidyl] suberate (BS3), a non-perme-
able crosslinking reagent. DHA treated cells exhibited a greater
than three-fold increase in dimerization compared to control and
LA treated cells (Figure 4B). This is consistent with previous
studies indicating that the lipid environment affects EGFR
dimerization [62], suggesting that the effect of DHA on EGFR
is due to the alteration in the lipid environment of the receptor,
resulting in increased EGFR dimerization and, therefore, phos-
phorylation.
We postulated that if the DHA-induced adaptive phosphoryla-
tion of EGFR is a result of membrane enrichment causing
disruption of lipid rafts, then the effect should be reversible by
depleting the cells of DHA. To test this hypothesis, cells were
treated with DHA, followed by a washout period wherein the cells
were either treated with no fatty acid or with LA. As expected, the
washout period resulted in significantly reduced levels of DHA in
the plasma membrane (Figure 4C), and ligand-induced EGFR
phosphorylation was normalized back to the same level as control
(Figure 4D). These data indicate that the inhibition of EGFR
the plasma membrane was fractionated into 3 distinct fractions, high density membrane (HDM), intermediate density membrane (IDM), and lipid raft
enriched membrane (LR) by gradient ultracentrifugation. Fractions were collected and an equal amount of protein from each fraction was analyzed
by Western blotting using antibodies against EGFR, caveolin-1, and clathrin or using peroxidase conjugated cholera toxin B subunit (for GM-1).
Quantification of band intensity was performed, and data are presented as the relative amount of EGFR in each fraction, with the sum of each fraction
equaling 100. Western blots are representative of 2 independent experiments. C, control; LA, linoleic acid; DHA, docosahexaenoic acid; PM, plasma
membrane; HDM, high density membrane; IDM, intermediate density membrane; LR, lipid raft enriched membrane. B) YAMC cells were treated with
50 mM BSA-complexed fatty acids for 72 h. Twenty-four h after initiating fatty acid treatment, cells were co-transfected with RFP-tH and EGFR-mGFP.
Approximately 32 h after transfection, cells were incubated in low serum media (0.5% FBS) overnight prior to imaging. Images are representative of 4
independent experiments. Whole cell images of each individual channel and the merged images are shown on the left. High magnification images of
the plasma membrane are shown on the right. Mander’s colocalization coefficient was calculated at the plasma membrane for the amount of EGFR-
mGFP (green) colocalizing with RFP-tH (red) using Nikon Elements AR 3.2. The coefficient is the mean of n= 30–40 cells per treatment. Statistical
significance between treatments (*P,0.05) was determined using ANOVA and Tukey’s test of contrast. Bars,10 mm.
doi:10.1371/journal.pone.0039682.g001
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signaling by DHA is dependent on its presence in the plasma
membrane.
DHA Inhibits EGF-stimulated Ras GTP-binding
Due to the fact that DHA treatment increased EGFR
phosphorylation while concurrently suppressing activation of
downstream mediators, we attempted to pinpoint the site of
perturbation in the signaling cascade. Since the EGFR-Ras-
ERK1/2 pathway is well documented, we examined the
components of this pathway downstream of the receptor.
Following EGF stimulation, growth receptor-bound protein 2
(Grb2) is recruited to the plasma membrane and binds to
phosphorylated tyrosine residues of EGFR (Tyr1068 and
Tyr1086). To assess recruitment of this immediate proximal signal
downstream of EGFR phosphorylation, cells were transfected with
fluorescently-tagged SH2 domain of Grb2 (Grb2-YFP), capable of
binding to the phosphorylated tyrosine residues of EGFR. Cells
were subsequently imaged using total internal reflective fluores-
cence (TIRF) microscopy to assess Grb2-YFP translocation to the
plasma membrane in response to EGFR activation. Following
stimulation with EGF, Grb2-YFP was rapidly recruited to the
plasma membrane (Figure 5A). We observed a significant increase
in EGF-stimulated Grb2-YFP plasma membrane translocation in
DHA treated cells compared to control and LA treated cells. Grb2
recruits Son of Sevenless (Sos), a guanine nucleotide exchange
factor (GEF), to activate Ras. Therefore, we assessed Ras
activation status by pulling-down GTP-bound Ras followed by
Western blotting for Ras. DHA-treated cells had significantly
Figure 2. DHA increases EGFR phosphorylation but suppresses activation of downstream signaling. YAMC cells were untreated
(control) or treated with 50 mM BSA-complexed fatty acids (LA or DHA) for 72 h. For the final 16–18 h, cells were incubated in low serum media (0.5%
FBS) with the same concentration of fatty acids. Cells were either unstimulated or stimulated for 10 min with 25 ng/mL EGF and subsequently
harvested. A) Equal amounts of protein from whole cell lysates were Western blotted for total and phosphorylated (Tyr1068) EGFR. Additionally, EGFR
was immunoprecipitated from total cellular lysates prior to Western blotting for EGFR and phosphorylated tyrosine resides. B) Whole cell lysates were
analyzed by Western blotting for total and phosphorylated downstream mediators of EGFR signaling, including ERK1/2, STAT3, S6kinase, and Akt.
Each blot is representative of 3–4 independent experiments with 3 replicates of each treatment per experiment. Quantification of band volume was
performed and data are presented as mean6SEM. Data are expressed as the ratio of the phosphorylated protein to total protein and normalized to
control. Statistical significance between treatments (*P,0.05; **P,0.01) was determined using ANOVA and Tukey’s test of contrast. C, control; LA,
linoleic acid; DHA, docosahexaenoic acid.
doi:10.1371/journal.pone.0039682.g002
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lower levels of GTP-bound Ras compared to control and LA-
treated cells (Figure 5B). This observation indicates that the DHA-
induced perturbation in the EGFR-Ras-ERK1/2 pathway occurs
at the site of Ras activation.
Ras is comprised of three distinct isoforms, including H-Ras, K-
Ras, and N-Ras. Isoform-specific signaling is regulated by
differential compartmentalization within cell surface microdo-
mains and intracellular compartments [60]. H-Ras is enriched in
lipid rafts, both caveolar and noncaveolar, whereas K-Ras is
exclusively located in the bulk membrane [59,60]. Additionally, N-
Ras is mainly segregated into noncaveolar lipid rafts [63].
Furthermore, Ras proteins have been shown to signal from the
Golgi complex, the endoplasmic reticulum, and endomembranes,
e.g., endosomes (9, 26, 32). The effect of this distinctive
segregation on the signals generated by Ras is just beginning to
unfold. Therefore, we assessed the effect of DHA on activation of
each Ras isoform to provide further clarity into the mechanism by
which DHA suppressed EGF-induced Ras activation. We found
that DHA suppressed activation of all three isoforms of Ras,
indicating a common mechanism by which DHA suppresses EGF-
induced activation of Ras. Furthermore, activation of H-Ras was
almost entirely inhibited by DHA, suggesting a distinct mechanism
of regulation for this specific isoform.
DHA Induces Increased EGFR Internalization and
Degradation
Endocytosis is a major mechanism of EGFR signal attenuation
by targeting the activated receptor for lysosomal proteolysis [64].
Figure 3. DHA uniquely alters EGFR function. YAMC cells were treated with control or 50 mM BSA-complexed fatty acids (LA or DHA) for 72 h.
For the final 16–18 h, cells were incubated in low serum media (0.5% FBS) with the same concentration of fatty acids. Cells were stimulated for 0–
30 min with 25 ng/mL EGF and subsequently harvested. Equal concentrations of protein from the whole cell lysates were analyzed by Western
blotting for A) phosphorylated EGFR, B) phosphorylated ERK1/2, and C) phosphorylated STAT3. Each immunoblot is representative of 3 independent
experiments. Quantification of band volume was performed and data are presented as mean6SEM and normalized to time 0 (n = 3). Statistical
significance between treatments (*P,0.05; **P,0.01) was determined using Student’s t-test. D) Additionally, YAMC cells were treated with 50 mM
BSA-complexed fatty acids (AA, EPA, or DHA) for a total of 72 h. For the final 16–18 h, cells were incubated in low serum (0.5% FBS) then stimulated
for 10 min with 25 ng/mL EGF. Whole cell lysates were separated assessed by Western blotting for phosphorylated (Tyr1068) EGFR. A representative
blot from 3 independent experiments is presented. Data are expressed as mean6SEM of phosphorylated EGFR, normalized to control (n = 3).
Statistical significance between treatments (P,0.05) is indicated by different letters and was determined using ANOVA and Tukey’s test of contrast. C,
control; LA, linoleic acid; DHA, docosahexaenoic acid; AA, arachidonic acid; EPA, eicosapentaenoic acid.
doi:10.1371/journal.pone.0039682.g003
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Recent evidence suggests that lipid rafts may play a role in
mediating EGFR endocytosis [65,66]. Additionally, EGFR
phosphorylation and Grb2 recruitment to EGFR are intimately
linked to EGFR internalization [67,68,69,70]. Therefore, we next
assessed the effect of DHA on EGFR endocytosis using a surface
biotinylation assay. Interestingly, internalization of EGFR oc-
curred more rapidly in DHA treated cells compared to untreated
(control) cells (Figure 6A). In addition, consistent with data in
Figure 4, A and B, DHA reduced the steady-state plasma
membrane localization of EGFR in unstimulated cells
(Figure 6B). Following internalization, EGFR can either be
recycled back to the cell surface or be targeted to the lysosome
for degradation. Ubiquitin acts as a sorting signal to down-regulate
the functions of plasma membrane proteins. EGFR internalization
and degradation are facilitated by ubiquitin [71]. Receptor
endocytosis stimulated by ubiquitination is considered to be
crucial to prevent oncogenesis because it sorts the receptor to the
lumen of multivesicular bodies and terminates growth factor
signaling [72]. This is especially crucial for EGFR since it has been
shown to continue to signal from endosomes after it is internalized
[67]. Therefore, we assessed ubiquitination of the receptor in
order to determine whether the DHA-induced increase in EGFR
internalization was associated with increased receptor ubiquitina-
tion and degradation. Immunoprecipitation of EGFR followed by
Western blotting for ubiquitin to assess EGFR ubiquitination was
utilized. We found that EGFR ubiquitination was significantly
Figure 4. DHA alterations to EGFR function require enrichment of DHA in the plasma membrane. A) Control treated YAMC cells were
incubated with low serum media overnight. Select cultures were then treated with 10 mM U0126 for 2 h. Untreated and U0126 treated cultures then
underwent stimulation with 25 ng/mL EGF for 10 min. Lysates were assessed by Western blotting for phosphorylation of Erk1/2 and EGFR (Tyr 1068).
B) Following stimulation with EGF, cells were subjected to chemical crosslinking prior to harvesting cell lysates. Cell lysate was assessed by Western
blotting for EGFR. EGFR dimers were identified as bands with twice the molecular weight of EGFR monomers. C-D) For ‘‘wash out’’ experiments,
YAMC cells were either untreated or treated with 50 mM DHA for 72 h. Select DHA treated cultures were then washed and incubated for an additional
40 h with either untreated media or 50 mM LA. For the final 16–18 h, cells were incubated with low serum media (0.5% FBS) followed by stimulation
with 25 ng/mL EGF then harvested. C) Membrane lipids were extracted and enrichment of membrane phospholipids with DHA was quantified by
capillary gas chromatography/mass spectrometry. D) Lysates were assessed by Western blotting for phosphorylated EGFR (Tyr1068). The blot is
representative of 3 independent experiments. Data are presented as mean6SEM of phosphorylated EGFR, normalized to control. Statistical
significance between treatments as indicated by different letters (P,0.05) was determined using ANOVA and Tukey’s test of contrast. C, control; AA,
arachidonic acid; EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid; LA, linoleic acid.
doi:10.1371/journal.pone.0039682.g004
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increased by DHA treatment (Figure 6C). Additionally, EGFR
expression was reduced in DHA treated cells 30 min after
stimulation. Together, these data suggest that DHA further
regulates EGFR signaling capacity by increasing EGFR internal-
ization and degradation.
Suppression of Cell Proliferation by DHA is EGFR-
dependent
In order to document a functional endpoint of the DHA-
induced decrease in EGFR signaling, we chose to measure cell
proliferation, which is regulated in part by signaling through
EGFR. DHA treatment of wild-type YAMC cells resulted in an
approximately 40% decrease in cell proliferation compared to
control and LA treated cells (Figure 7A). We additionally assessed
whether expression of a constitutively active form of H-Ras (GFP-
H-RasG12V) could rescue the DHA-induced suppression of cell
proliferation. We found that DHA-treated cells expressing
constitutively activated H-Ras recovered partially from the
DHA-induced suppression of cell proliferation but still exhibited
approximately a 15% decrease in cell proliferation compared to
control cells expressing GFP-H-RasG12V. Additionally, the effect
of DHA on proliferation of an isogenic cell line that does not
express EGFR (EGFR2/2) was assessed. Interestingly, DHA
treatment had no effect on cell proliferation in EGFR2/2 YAMC
cells compared to control. Together, these data demonstrate that
DHA suppresses cell proliferation in an EGFR-dependent
manner. Based on these findings, we have developed a putative
model illustrating the effects of DHA on EGFR (Figure 7B).
Fish Oil Inhibits EGFR Signaling in Mouse Colonic Mucosa
In order to further corroborate the effects of DHA on EGFR
activation status, we evaluated the status of total and phosphor-
ylated EGFR in colonic mucosa from carcinogen-injected
(azoxymethane), chronically-inflamed (dextran sulfate sodium
treated) C57BL/6 mice fed diets enriched in fish oil (containing
DHA) or corn oil (control, contains primarily LA and no n-3
polyunsaturated fatty acids). Protein lysates from the uninvolved
colonic mucosa were collected and probed for total and
phosphorylated EGFR (Tyr1068) by Western blotting. Addition-
ally, we performed immunoprecipitation for EGFR followed by
Western blotting for phosphorylated tyrosine residues. Consistent
with the cell culture data, phosphorylation of EGFR increased
approximately two-fold in mice fed a fish oil diet compared to
mice fed a corn oil diet, while no difference in the total expression
of EGFR was observed (Figure 8A). We further probed tissue
lysates for phosphorylation of ERK1/2, STAT3, and Akt. Similar
to Figure 1 data, phosphorylation of ERK1/2 and STAT3
decreased by approximately 40% and 50%, respectively, in fish oil
fed mice compared to corn oil fed mice with no difference in
phosphorylation of Akt between diets (Figure 8A). Additionally,
tumors from the animals were stained and typed. Interestingly, fish
oil fed animals developed fewer tumors compared to animals fed a
corn oil diet (Figure 8B). Overall, these data indicate a protective
effect of dietary fish oil against colon tumorigenesis by suppressing
EGFR signal transduction.
Discussion
EGFR is a transmembrane receptor tyrosine kinase involved in
transmitting external cues to the intestinal epithelium, thereby
modulating cell proliferation, migration, and survival. Recent
evidence suggests that the membrane lipid microenvironment can
significantly modulate EGFR localization and function [62]. Here,
we report that membrane incorporation of DHA alters the lateral
organization of EGFR (Figure 1). The lateral organization of the
receptor has been shown to directly regulate ligand binding,
dimerization, and receptor phosphorylation [5,6,9]. Consistent
with these observations, we demonstrated that DHA treatment
resulted in increased ligand-stimulated EGFR dimerization and
phosphorylation (Figures 2A and 4B). Therefore, the DHA-
induced shift of EGFR localization within the plasma membrane
alters the ability of the receptor to dimerize and transpho-
sphorylate. These findings favor a model according to which
receptor modulation by fatty acids is mediated by the membrane.
According to the canonical process of signal transduction, the
observed increase in EGFR phosphorylation upon treatment with
DHA is expected to be correlated with enhanced downstream
signaling. Two previous studies have observed that DHA increases
EGFR phosphorylation, but they reported conflicting results
regarding downstream signaling [54,55]. Additionally, the flawed
design of one of the studies renders the results difficult to interpret.
Therefore, in our study, we evaluated the effect of DHA on
activation of multiple distinct signaling cascades that radiate from
EGFR within the colon. Although DHA was found to increase
EGFR phosphorylation, we noted that this fatty acid uniquely
inhibited EGF-stimulated activation of downstream signaling from
EGFR through ERK1/2, STAT3, and mTOR/S6K (Figure 2B).
A substantial body of work has documented the central role of
lateral membrane organization in mediating EGFR signal
transduction [73]. Integral to EGFR signaling is its localization
to lipid raft domains. These specialized membrane domains have
the ability to assemble the molecular machineries necessary for
intracellular propagation of EGFR effector signals. Stimulation
with EGF induces coalescence of lipid raft domains and promotes
the formation of these signaling platforms, which suggests a central
role for these domains in EGFR signal propagation [74].
Collectively, these data suggest that by altering the lateral
organization of EGFR, DHA can modulate multiple cellular
signaling cascades.
In addition to regulating the localization of EGFR within the
plasma membrane, DHA also altered the subcellular distribution
of EGFR. Under unstimulated conditions, DHA treated cells
contained significantly less EGFR at the plasma membrane
Figure 5. DHA impairs EGF-induced activation of Ras. A) YAMC cells were treated with 50 mM BSA-complexed fatty acids for 72 h. Twenty-four
h after initiating fatty acid treatment, cells were transfected with Grb2-YFP. For the final 16–18 h, cells were incubated with low serum media (0.5%
FBS) with the same concentration of fatty acids and imaged using TIRF microscopy. Cells were stimulated with 100 ng/mL EGF and imaged every
5 sec. Images are representative of 4 independent experiments (n = 22225 cells/treatment). Changes in total surface intensity were quantified using
Nikon Elements AR 3.2. Fluorescence images and the respective surface intensity plots are shown. Surface intensity plots were generated in Nikon
Elements AR 3.2 (the scale is from blue (lowest intensity) to red/pink (highest intensity). Data are presented as mean6SEM normalized to control.
Bars, 10 mM. B) YAMC cells were treated with 50 mM BSA-complexed fatty acids for 72 h. For the final 16–18 h, cells were incubated with low serum
media (0.5% FBS) with the same concentration of fatty acids. Cells were stimulated with 25 ng/mL EGF for 2 min and harvested. GTP-bound Ras was
isolated using a GST pull-down assay. Isolated GTP-bound Ras was then analyzed by Western blotting for pan Ras. Isolated GTP-bound Ras was
additionally analyzed by Western blotting for H, K, and N-Ras. Blots are representative of 3 independent experiments. Quantification of band volume
was performed. Data are expressed as mean6SEM (n = 3), normalized to control. Statistical significance between treatments (P,0.05) as indicated by
different letters was determined using ANOVA and Tukey’s test of contrast. C, control; LA, linoleic acid; DHA, docosahexaenoic acid.
doi:10.1371/journal.pone.0039682.g005
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(Figure 6B). Additionally, concomitant with increased EGFR
phosphorylation, DHA treated cells exhibited enhanced EGFR
endocytosis following receptor stimulation (Figure 6A). Because a
majority of signaling cascades are activated by EGFR at the
plasma membrane, receptor endocytosis and degradation play
important roles in terminating EGFR signaling. Therefore, the
DHA-mediated enhancement of EGFR internalization is an
additional mechanism by which DHA can suppress the ability of
EGFR to activate downstream signaling. Once internalized,
EGFR can continue signaling from endosomes, recycle back to
the plasma membrane, or traffic for degradation. This is
noteworthy because DHA increased EGFR ubiquitination and
degradation (Figure 6C). Interestingly, although DHA treatment
did not affect the steady-state levels of EGFR, following ligand-
induced activation, it significantly increased EGFR ubiquitinata-
tion and degradation. Since receptor endocytosis and degradation
can function to mitigate signal transduction, we propose that this is
an additional mode by which DHA modulates the signaling
capacity of EGFR.
To further understand the mechanism by which DHA
suppresses EGFR signal transduction, we attempted to identify
the exact locus of the DHA-induced perturbation in EGFR signal
transduction. Therefore, we assessed the individual components of
the EGFR-Ras-ERK1/2 signaling axis. Grb2 is an immediate
proximal downstream mediator of EGFR signaling and directly
binds to phosphorylated tyrosine residues of EGFR, including
Tyr1068, which we showed here to be increased by DHA
treatment. Grb2 mediates multiple responses to EGFR phosphor-
ylation, including propagation of intracellular signaling and
receptor endocytosis. We observed that DHA treatment increased
Figure 6. DHA mediates increased EGFR internalization and degradation. YAMC cells were incubated with untreated media or media
supplemented with 50 mM BSA-complexed DHA for a total of 72 h. For the final 16–18 h, cells were incubated with low serum media (0.5% FBS). A)
Cell surface proteins were labeled with EZ-Link Sulfo-NHS-SS-Biotin followed by stimulation with 25 ng/mL EGF for 0–30 min. After stimulation, cells
were washed and biotin remaining on the cell surface was cleaved. Cell lysates were harvested, and biotinylated EGFR was quantified by ELISA using
streptavidin coated plates and anti-EGFR antibody. B) Cell surface EGFR was assessed by treating cells the same as in A, and harvesting without
stimulating with EGF or cleaving cell surface biotin. C) Cells were stimulated with 25 ng/mL EGF for 0–30 min and harvested. EGFR was
immunoprecipitated from the total cell lysate, assessed by Western blotting for ubiquitin, and quantification of band intensity was performed. All
results are representative of at least 3 independent experiments. Data represent mean6SEM. In (A) and (C), data are normalized to time 0. In B), data
are normalized to control (no fatty acid). Statistical significance between treatments (*P,0.05. **P,0.01) was determined using Student’s t-test. C,
control; DHA, docosahexaenoic acid.
doi:10.1371/journal.pone.0039682.g006
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Figure 7. DHA suppresses EGFR-mediated cell proliferation. A) Wild-type and EGFR2/2 YAMC cells were treated with 50 mM BSA-complexed
fatty acid for 24 h. Following the initial treatment, cells were seeded at an equal density into a 96-well plate, and cultured under the same treatment
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the EGF-stimulated recruitment of Grb2 to the plasma membrane
(Figure 5A), indicating that DHA does not affect the ability of
phosphorylated EGFR to recruit intracellular signaling mediators.
We subsequently demonstrated that the breakpoint in the DHA-
mediated suppression of EGFR signaling was at the level of Ras
activation (Figure 5B). Our lab has previously shown that DHA
suppresses the levels of activated GTP-bound Ras under basal
conditions [75]. We have extended these observations by
conditions for an additional 48 h. Select cultures were transfected using nucleofection with GFP-H-RasG12V prior to being seeded into the 96-well
plate. Cell proliferation was measured using CyQUANT cell proliferation assay. Results are representative of 3 independent experiments. Data are
expressed as mean6SEM (n = 9 samples per treatment). Statistical significance between treatments as indicated by different letters (P,0.05) was
determined using ANOVA and Tukey’s test of contrast. No comparisons were made between proliferation of wild-type and EGFR2/2 cells. B) Putative
model: Under control conditions, EGFR is enriched in liquid ordered lipid raft domains of the cell. Upon stimulation, ligand bound receptors dimerize
and transphosphorylate. The phosphorylated tyrosine residues then serve as docking sites for adaptor proteins, which leads to the activation of
downstream targets, including Ras. Signaling is efficient due to the lateral organization of EGFR and downstream signaling partners. Upon fatty acid
treatment, the cell incorporates DHA into plasma membrane phospholipids. DHA is sterically incompatible with cholesterol and perturbs liquid
ordered domains resulting in a change in the lateral organization of EGFR. Ligand-induced receptor dimerization and phosphorylation is increased,
along with receptor ubiquitination, internalization, and degradation. The altered lateral and subcellular organization of EGFR results in inefficient cell
signaling. Suppression of EGFR signaling causes altered cellular function, including reduced cell proliferation.
doi:10.1371/journal.pone.0039682.g007
Figure 8. Fish oil feeding suppresses colonic epithelial EGFR signaling in mice. Carcinogen (AOM) and DSS-treated mice were fed a diet
enriched in fish oil (high in DHA) or corn oil (contains no DHA) for a total of 15 weeks. A) Whole cell lysates were isolated from scraped colonic
mucosa. Equal concentrations of protein were assessed by Western blotting for total and phosphorylated EGFR (Tyr1068). Additionally, EGFR was
immunoprecipitated from mucosal lysates and Western blotted for phosphorylated tyrosine residues and EGFR. Also, whole cell lysates were probed
by Western blotting for total and phosphorylated downstream mediators of EGFR signaling, including ERK1/2, STAT3, and Akt. Quantification of band
volume was performed and data are presented as mean6SEM of the ratio of phosphorylated protein to total protein and normalized to CO, n = 12
mice per diet. B) Colon lesions were fixed in 4% paraformaldehyde, embedded in paraffin, stained with hematoxylin-eosin, and evaluated by a board
certified pathologist. The mean colon tumor entity number, including adenomas and adenocarcinomas, per mouse in each diet treatment is
presented, n = 22225 mice per diet. Statistical significance between diets was determined using Student’s t-test. CO, corn oil; FO, fish oil.
doi:10.1371/journal.pone.0039682.g008
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demonstrating that EGFR-mediated activation of all three
isoforms of Ras was suppressed by DHA. In addition, DHA had
the strongest inhibitory effect on activation of H-Ras. This is
intriguing due to the fact that both H-Ras and EGFR are localized
to lipid rafts [59], and that EGF-stimulated interactions between
Ras and its downstream partner Raf-1 have been shown to occur
in lipid rafts [3]. A potential explanation for the observed DHA-
mediated suppression of activation of Ras, specifically H-Ras, is
based on the altered localization of EGFR within the plasma
membrane. Convincing evidence illustrates the importance of
lateral segregation of signaling cascades on the plasma membrane.
Indeed, for signal transduction to occur, phosphorylated EGFR
must form a transient complex with Grb2, Sos, and Ras [76]. Due
to the altered plasma membrane localization of EGFR upon
treatment with DHA, this could result in a spatial abrogation of
signal transduction by reducing the formation of these transient
complexes.
Since DHA antagonizes the activation of all Ras isoforms
regardless of their plasma membrane localization, it is likely that
an additional mechanism mediates the suppression of EGFR
signal transduction by DHA. Therefore, we hypothesize that the
observed increased endocytosis of the receptor contributes to the
suppressive phenotype. The majority of activation of Ras by
EGFR has been shown to occur at the plasma membrane [77].
Therefore, the observed DHA-induced increase in EGFR
internalization likely contributes to the reduced activation of all
Ras isoforms. We are currently determining whether the altered
plasma membrane localization of EGFR and/or enhanced EGFR
endocytosis are responsible for the suppression of downstream
signaling. Additionally, further work is required to determine how
the altered plasma membrane localization of EGFR contributes to
enhanced receptor internalization and degradation. Previous work
by Sigismund et al. indicates that high levels of EGFR
phosphorylation can lead to activation of additional forms of
EGFR endocytosis which sort EGFR for degradation instead of
recycling [66]. Therefore, it is possible that DHA could function
by altering EGFR plasma membrane localization, resulting in
higher levels of EGFR phosphorylation and activation of a non-
canonical form of receptor endocytosis that sorts the receptor for
degradation as opposed to recycling. Current studies in our lab are
focused on testing this hypothesis.
These results have substantial biological relevance because Ras
plays a central role in the development of human colon cancer and
is commonly hyperactivated by somatic mutation or signaling
through growth factor receptors [78]. Hence, by suppressing EGF-
stimulated activation of Ras, DHA can provide protection against
colonic transformation. In addition to suppressing activation of the
Ras-ERK1/2 pathway, DHA suppressed EGF-stimulated activa-
tion of STAT3. STAT3 can be activated downstream of EGFR by
several pathways, and Ras signaling has been shown to be
intimately linked to STAT3 activation [79,80,81]. Therefore, the
reduction in STAT3 activation could be a direct result of reduced
activation of Ras. Additionally, lipid rafts have been shown to play
a central role in the activation of STAT3 [82], which may explain
the DHA-induced suppression of STAT3 activation. Clearly,
further studies are required to determine the exact mechanism of
action.
To analyze the consequence of the suppression of EGFR
signaling by DHA, we measured cell proliferation in wild-type and
EGFR-null colonocytes. Interestingly, DHA suppressed cell
proliferation only in cells with a functional EGFR (Figure 7A).
These results indicate that the DHA modulates cell proliferation in
an EGFR-dependent manner. It is important to note that DHA
does not induce apoptosis in this cell line [83], so the changes
observed are due to suppressed proliferation and not increased cell
death. Additionally, expression of a constitutively active form of H-
Ras partially rescued the DHA-induced suppression of cell
proliferation. The limited ability of constitutively active H-Ras
was likely due to the inhibitory effect that DHA has on other
downstream pathways from EGFR that are independent of Ras
signaling. Based on these data, we have developed a putative
model according to which DHA alters the cellular localization and
signaling capacity of EGFR (Figure 7B). By altering the lateral
organization of EGFR, DHA enhances the ability of EGFR to
dimerize and transphosphorylate. DHA also increases EGFR
internalization and degradation, which suppresses the ability of
EGFR to activate downstream signaling cascades.
In order to determine the in vivo effect of DHA on EGFR
signaling, we assessed whether dietary consumption of fish oil,
enriched in DHA, modulates EGFR phosphorylation and
signaling in mice. Consistent with our cell culture data, feeding
a DHA-enriched diet resulted in an increase in EGFR phosphor-
ylation and a suppression of ERK1/2 and STAT3 activation in
mouse colonic epithelium (Figure 8). The suppression of EGFR
signaling in the colon was associated with a reduction in tumor-
incidence in mice fed a DHA-enriched diet. These data highlight
the unique mechanism by which DHA suppresses colon tumor-
igenesis.
The differential effects of DHA and EPA, the two n-3 PUFAs
enriched in fish oil, are often overlooked and underappreciated.
Therefore, we assessed whether EPA had the same effect as DHA
on EGFR phosphorylation. Interestingly, in contrast to DHA,
neither EPA nor AA, another long-chain PUFA, exerted an effect
on EGFR phosphorylation (Figure 3D). This is consistent with a
previous study showing that DHA, but not EPA, suppressed EGF-
stimulated activation of AP-1 [84]. Collectively, these results
highlight the uniqueness of DHA, which has been shown to
significantly alter numerous membrane properties [48,49]. The
effects of DHA on EGFR signaling are reversible when
supplementation with DHA is discontinued and the fatty acid is
washed out of the plasma membrane (Figure 4D). This is
consistent with our hypothesis that DHA enrichment in the
plasma membrane directly modulates EGFR signaling. DHA is a
structurally unique fatty acid. It is slightly polar due to its six
double bonds, and it rapidly reorients through multiple confor-
mational states [48]. This flexible structure renders DHA
incompatible with ordered saturated acyl chains and cholesterol,
two major constituents of lipid rafts. Multiple biophysical studies
utilizing model membranes and molecular dynamic simulations
have shown that DHA acyl chains do not pack efficiently with
cholesterol and saturated acyl chains [85,86]. Additionally, studies
using cell lines have demonstrated that DHA can disrupt lipid rafts
and alter protein distribution [52,53,87]. Although, the exact effect
that DHA has on lipid rafts remains to be fully elucidated, an
abundance of data clearly demonstrate that DHA can impede lipid
raft mediated processes and alter lipid raft composition [47,54].
Our data demonstrate that DHA inhibits the lateral organization
of EGFR within the plasma membrane. Furthermore, the data
suggest that DHA modifies lipid rafts because it altered the overall
localization of the lipid raft marker, RFP-tH, within the plasma
membrane. Overall, this work provides further evidence of the
global effect of DHA on lipid rafts.
A seminal finding of this work is the DHA-induced severance of
EGFR phosphorylation from downstream signaling. Phosphory-
lation of EGFR has previously been considered a marker for
activation of downstream signaling. In contrast, our data describe
a mechanism whereby DHA induces an increase in EGFR
phosphorylation by altering its localization but suppresses down-
Regulation of EGFR Signal Transduction
PLoS ONE | www.plosone.org 13 June 2012 | Volume 7 | Issue 6 | e39682
stream signaling. Further understanding of the relationship
between plasma membrane composition and receptor organiza-
tion is required to fully elucidate the regulation of cell signaling.
The interactions between cellular membranes and signaling
proteins are emerging as important for mediation of cellular
signaling [88,89]. Indeed, cell surface spatio-temporal organiza-
tion is fundamentally dependent on the targeting of proteins to
specialized membrane domains, as well as the dynamics of these
protein-membrane associations. Ultimately, the intimate relation-
ship of signaling proteins and membranes enables intricate control
and refinement of biological processes. Based on the work
presented here, fatty acids, specifically DHA, play a central role




Young adult mouse colonic (YAMC) cells, conditionally immor-
talized colonocytes, were originally obtained fromR.H.Whitehead,
LudwigCancer Institute (Melbourne, Australia). Bothwild-type and
EGFR2/2 isotype YAMC cells were utilized. YAMC cells (passages
12–17) were cultured under permissive conditions, 33uC and 5%
CO2 in RPMI 1640 media (Mediatech, Manassas, VA) supple-
mented with 5% fetal bovine serum (FBS; Hyclone, Logan, UT),
2 mM GlutaMax (Gibco, Grand Island, NY), 5 mg/mL insulin,
5 mg/ml transferrin, 5 ng/ml selenious acid (Collaborative Bio-
medical Products, Bedford, MA), and 5 IU/mL of murine
interferon-c (Roche, Mannheim, Germany). Select cultures were
treated for 72 h with 50 mM fatty acid [DHA, linoleic acid (LA,
18:2n26), arachidonic acid (AA, 20:4n26), or eicosapentaenoic
acid (EPA, 20:5n23); NuChek, Elysian, MN] complexed with
bovine serum albumin (BSA). Where indicated, DHA treated
cultures were washed three times with PBS followed by incubation
with untreatedmedia or LA for an additional 40 h. In select cultures,
for the final 16–18 h, complete media was replaced with low-serum
(0.5% FBS) media. Cells were then stimulated with 0–25 ng/mL
recombinant mouse EGF (Sigma, St. Louis, MO) and harvested. In
select cultures, cells were incubated with the ERK1/2 inhibitor
U0126 (Invitrogen, Grand Island, NY) at 10 mM for 2 h prior to
stimulation with EGF.
Lipid Raft Isolation
To determine the localization of EGFR within the plasma
membrane, YAMC cells were treated with fatty acid and
incubated with low serum media as above. Detergent-free lipid
raft-enriched fractions were isolated as previously described
[57,58]. All steps were performed at 4uC. YAMC cells grown in
12 T-175 flasks per treatment were harvested with trypsin-EDTA
(Gibco) and pelleted at 2006g for 5 min. The pellets were
resuspended in Buffer A (250 mM sucrose, 1 mM EDTA,
20 mM tricine, 100 mM activated sodium orthovanadate,
40 mL/mL protease cocktail, pH 7.8) at 16107 cell/mL. Cells
from each treatment were pooled and lysed by two rounds of
rapid freeze (280uC) and thaw (37uC). Cell lysates were then
centrifuged at 10006g for 10 min, and the supernatants were
retained. Cell pellets were resuspended in Buffer A and
homogenized as above, and the centrifugation step was repeated.
The resulting supernatants were pooled into a post-nuclear
supernatant (PNS). The PNS was layered on top of 30% Percoll
(Amersham, Pittsburg, PA) in Buffer A and centrifuged at
84,0006g for 30 min in a Beckman SW28 rotor. The plasma
membrane fraction was collected and sonicated 3 times (50-J
bursts) with 2 rapid pulses each time. The samples were then
mixed with OptiPrep (Accurate Chemical and Scientific Corp,
Westbury, NY) in Buffer A (final concentration 23%), overlaid
with a 6 mL linear 20 to 10% OptiPrep gradient, and
centrifuged in a Beckman SW41Ti rotor at 52,0006g for
90 min. The top 5 mL of the gradient was collected and
combined with 4 mL of 50% OptiPrep in Buffer A. An aliquot of
the denser membrane band (HDM) was collected. The 9 mL
fraction was overlaid with 1 mL of 15% Optiprep in Buffer A
and 0.5 mL of 5% Optiprep in Buffer A and was centrifuged at
52,000 g for 90 min in a Beckman SW41Ti rotor. A lipid raft/
caveolae-enriched membrane fraction (LR) was collected from
the 5/15% interface, and a membrane fraction defined as the
intermediate fraction (IDM) was collected at the bottom of the
15% layer. Slide-a-lyser cassettes (Pierce, Rockford, IL) were
used to dialyze samples overnight in dialysis buffer (1 mM
EDTA, 20 mM tricine, pH 7.8). Samples were placed into
1.5 mL Eppendorf tubes and centrifuged in a SpeedVac System
to 1/3 the original volume to concentrate. Protein concentration
was measured with Coomassie Plus Protein assay (Pierce), and
fractions were subjected to SDS-PAGE and Western blotting as
described above.
Colocalization
The plasmid containing RFP conjugated with a truncated H-
Ras composed of the C-terminal 9 amino acid targeting domain
(RFP-tH) was a generous gift from Ian Prior, Univ. of Liverpool
[90]. The plasmid containing full length human EGFR conjugated
to GFP containing a point mutation of A206K in the GFP
sequence to prevent GFP dimerization (EGFR-mGFP) was a kind
gift from Hung-Jun Liao, Vanderbilt University [91]. Cells were
seeded at a density of 1.06105 cells per well into Lab-Tek II 2-well
chambered coverglass slides (Nalge Nunc, Rochester, NY) 24 h
prior to transfection and cultured in complete RPMI media
containing 50 mM fatty acid. Cells were cotransfected with 0.3 mg
RFP-tH and 1.5 mg EGFR-mGFP using Effectene (Qiagen,
Valencia, CA) in media without fatty acid according to the
manufacturer’s instructions. Transfection conditions were opti-
mized to minimize the amount of DNA and lipofection reagent
used to avoid nonspecific cytotoxicity. Four h after transfection,
cells were washed and the media was replaced and supplemented
with 50 mM fatty acid for 48 h. Cells were incubated in low serum
media (0.5% FBS) with fatty acid for the final 16–18 h prior to
imaging. Cells were imaged 48 h after transfection. Prior to
imaging, cultures were washed with Leibovitz’s L-15 medium
(Gibco) followed by addition of 1 mL of Leibovitz’s media (without
serum) per well. Images were collected with a Zeiss 510 META
NLO Multiphoton Microscope System consisting of an Axiovert
200 MOT microscope (Carl Zeiss Microimaging, Thornwood,
NY) equipped with an argon laser, PMT, and LSM software. For
EGFR-mGFP and RFP-tH, excitation wavelengths of 488 nm and
543 nm were used, and fluorescence emission was monitored at
530 nm and 590 nm, respectively. Images were collected in
confocal mode with the pinhole set at 1 AU using a 406objective
(1.3 NA oil immersion lens) at room temperature. Identical
acquisition parameters were used for all images within the
experiment. Colocalization at the plasma membrane was analyzed
by quantifying Mander’s colocalization coefficient for green
(EGFR-mGFP) with red (RFP-tH) using Nikon Elements AR
3.2. Analysis was performed on background-subtracted 16-bit
images.
Western Blotting
For Western blotting, cells were homogenized in ice-cold
homogenization buffer (50 mM Tris-HCl, pH 7.2, 250 mM
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sucrose, 2 mM EDTA, 1 mM EGTA, 50 mM sodium fluoride,
100 mM sodium orthovanadate, 1%Triton X-100, 100 mM
activated sodium orthovanadate, 10 mM b-mercaptoethanol,
and protease inhibitor cocktail) as previously described [92].
Following homogenization, lysates were sheared using a 29G
needle, incubated on ice for 30 min, and centrifuged at 16,0006g
for 20 min. The supernatant was collected and protein concen-
tration was assessed using Coomassie Plus Protein assay (Pierce).
Lysates were treated with 16pyronin sample buffer and subjected
to SDS polyacrylamide gel electrophoresis (PAGE) in precast 4–
20% Tris-glycine mini gels (Invitrogen). After electrophoresis,
proteins were electroblotted onto a polyvinylidene fluoride
membrane with the use of a Hoefer Mighty Small Transphor
unit at 400 mA for 90 min. Following transfer, the membrane was
incubated in 5% BSA (Roche) and 0.1% Tween 20 in TBS
(TBST) at room temperature for 1 h with shaking, followed by
incubation with shaking overnight at 4uC with primary antibody
diluted in 5% BSA in TBST. Membranes were washed with
TBST and incubated with secondary peroxidase conjugated
secondary antibody as per manufacturer’s instructions. Bands
were developed using Pierce SuperSignal West FemtoTM maxi-
mum sensitivity substrate. Blots were scanned using a Fluor-S Max
MultiImager system (Bio-Rad, Hercules, CA). Quantification of
bands was performed using Quantity One software (Bio-Rad).
Monoclonal rabbit anti-EGFR, phospho-EGFR (Tyr1068), Akt,
phospho-Akt (Ser473), ERK1/2, p-ERK1/2, STAT3, phospho-
STAT3 (Tyr705), p70 S6kinase, and phospho-p70 S6kinase
(Thr389) and monoclonal mouse phospho-tyrosine were pur-
chased from Cell Signaling (Danvers, MA). Monoclonal mouse
anti-ubiquitin and polyclonal rabbit anti-K, H, and N-Ras were
purchased from Santa Cruz (Santa Cruz, CA). Affinity purified
mouse anti-clathrin heavy chain and purified mouse anti-caveolin
1 were purchased from BD Transduction Laboratories (Bedford,
MA). Peroxidase conjugated goat anti-rabbit IgG was purchased
from Kirkegaard and Perry Laboratories (Gaithersburg, MD), and
peroxidase conjugated goat anti-mouse IgG was purchased from
Jackson ImmunoResearch (West Grove, PA). For detection of
ganglioside GM-1, peroxidase conjugated cholera toxin B subunit
was purchased from Sigma.
Immunoprecipitation
Cell lysates were incubated with rotation purified polyclonal
rabbit anti-EGFR antibody (Millipore, Billerica, MA) overnight.
The protein-antibody conjugates were then pulled down using
protein-G conjugated Dynabeads (Invitrogen). Protein was eluted
from the dynabeads using 26 pyronin buffer, and equal volumes
of the samples were run on SDS-PAGE and Western blotted for
EGFR, phospho-tyrosine, or ubiquitin. Lysates analyzed for
ubiquitination of EGFR were treated with 5 mM N-ethylmalei-
mide to prevent post lysis deubiquitination of EGFR [61].
Receptor Dimerization
To assess EGFR dimerization, cells were treated as above.
Following low serum incubation, cells were washed with ice-cold
PBS prior to incubation with 0 or 25 ng/mL EGF on ice for 1 h.
Cells were then washed with ice-cold PBS followed by incubation
on ice for 20 min with 3 mM bis(sulfosuccinimidyl) suberate (BS3,
Pierce), a non-permeable crosslinking reagent. In all experiments,
a freshly prepared solution of BS3 was used. The crosslinking
reaction was quenched by adding 250 mM glycine in PBS and
further incubation on ice for 5 min. Cells were washed with PBS
and homogenized as above. Protein concentration was measured
and lysates were assessed by Western blotting for EGFR as
described above.
Fatty Acid Analysis
To assess incorporation of DHA into phospholipids, membrane
lipids were extracted with chloroform-methanol (2:1 vol/vol), and
total phospholipids were separated by thin-layer chromatography
with chloroform-methanol-acetic acid-water (90:8:1:0.8 vol/vol/
vol/vol). After transesterification, fatty acid methyl esters were
quantified by capillary gas chromatography/mass spectrometry
[93].
Total Internal Reflective Fluorescence (TIRF) Microscopy
A plasmid containing the SH2 domain of Grb2 conjugated to
YFP (Grb2-YFP) was generously provided by Alexander Sorkin,
University of Colorado [94]. For TIRF experiments, cells were
treated with fatty acids for 24 h prior to transfection. Cells were
transfected using Amaxa nucleofection kit L (Amaxa, Basel,
Switzerland) with 2.0 mg Grb2-YFP. Following transfection, cells
were seeded at a density of 25,000 cells/well into MatTek
(Ashland, MA) glass bottom 35 mm dishes in the presence of fatty
acid. Approximately 32 h after transfection, cells were incubated
in low serum media (0.5% FBS) containing fatty acid for 16–18 h
prior to imaging. Images were acquired on a Zeiss TIRF
Microscope system consisting of a Zeiss AxioObserver Z1
microscope (Carl Zeiss) equipped with a high resolution AxioCam
MRm camera, argon laser, and AxioVision 4 software. An
excitation wavelength of 514 nm was used, and emission was
monitored at 537 nm. All images were collected using a 1006
objective (1.4 NA oil immersion) at 37uC and 5% CO2. To
observe the translocation of Grb2-YFP to the plasma membrane,
cells were stimulated with 100 ng/mL EGF, and images were
collected every 5 sec. Images were collected using identical image
acquisition parameters for all images within the experiment.
Whole cell fluorescence intensity was performed on background-
subtracted 16-bit images using Nikon Elements AR 3.2.
Ras Activation Assay
To assess the activation status of Ras, YAMC cells were treated
for 72 h with fatty acid and incubated with low serum media
(0.5% FBS) for the final 16–18 h. Cells were stimulated with
25 ng/mL EGF for 2 min, then harvested using Pierce cell lysis
buffer. Activated (GTP-bound) Ras was subsequently isolated and
assessed by Western blotting using the Pierce Active Ras Pull-
Down and DetectionTM kit according to the manufacturer’s
instructions. Additionally, Ras isoforms were detected by Western
blotting the isolated GTP-bound Ras using isoform specific
antibodies as described above.
Biotinylation
To assess cell surface EGFR and receptor internalization, cells
were treated with fatty acids, incubated with low serum media and
surface biotinylated using thiol-cleavable EZ-Link Sulfo-NHS-SS-
Biotin (Pierce), 0.5 mg/mL, dissolved in PBS for 30 min on ice.
Labeled cells were then rinsed two times with ice-cold PBS, and
excess biotin was quenched with 60 mM iodoacetamide in PBS
buffer for 5 min at 4uC. Select cultures were harvested at this step
in order to quantify cell surface expression of EGFR. Cells were
then washed three times with ice-cold PBS, followed by incubation
at 33uC in prewarmed serum-free RPMI media for 5 min followed
by stimulation with 25 ng/mL EGF for 0–30 min. Biotin groups
remaining on the cell surface were then cleaved off by three
20 min washes with buffer containing reducing agent [100 mM
MESNA (sodium-2-mercaptoethane sulfonate), 50 mM Tris
(pH 8.6), 100 mM NaCl, 1 mM EDTA, and 0.2% BSA] at 4uC.
Cells were then washed three times in ice-cold PBS and lysed in
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RIPA buffer (20 mM Tris, 150 mM NaCl, 2 mM EDTA, 2 mM
EGTA, 1% sodium deoxycholate, 1% SDS, and 1% Triton X-
100) containing protease and phosphatase inhibitors. The lysates
were clarified by centrifugation at 16,0006g for 20 min. Protein
concentration was assessed using BCA protein assay (Pierce).
Biotinylated EGFR was captured on streptavidin ELISA plates
(NUNC IMMOBILIZER Streptavidin C8) from the cell lysates
diluted to 5 mg/mL total protein in PBS containing 0.5% Tween
20, pH 7.3 (PBST), during a 2 h incubation at room temperature
on a shaker. Plates were then washed three times with PBST,
incubated with anti-EGFR antibody (Santa Cruz) (2 mg/mL) for
2 h at room temperature, washed, and incubated with horseradish
peroxidase-conjugated secondary antibody for 1 h at room
temperature. The plates were subsequently washed three times
in PBST before adding color substrate (R&D Systems, Minneap-
olis, MN) for 5–10 min. Color development was stopped by
addition of an equal amount of 4 M H2SO4 and analyzed at
450 nm.
Cell Proliferation
YAMC cells (both wild-type and EGFR2/2) were treated with
fatty acids for 24 h prior to being seeded into a 96-well plate at a
density of 1.06105 cells per well. Cells were cultured in complete
media supplemented with fatty acids for an additional 48 h.
Additionally, wild-type YAMC cells were transfected using
nucleofection (Amaxa kit L) with a constitutively active form of
H-Ras (H-RasG12V-GTP), provided by Dr. Ian Prior [95], prior
to being seeded into a 96 well plate and cultured for 48 h. Cells
were then washed with PBS and cell proliferation was measured
using CyQuant cell proliferation assay (Molecular Probes, Grand
Island, NY) according to the manufacturer’s instructions.
Mice
Female C57BL/6 wild-type mice were used. All procedures
followed guidelines approved by the U.S. Public Health Service
and the Institutional Animal Care and Use Committee at Texas
A&M University. This study and all animal protocols and
procedures were approved by the Institutional Animal Care and
Use Committee at Texas A&M University (Permit number:
AUP2010-079). All efforts were made to minimize suffering. Mice
were maintained under barrier conditions and initially consumed a
Teklad commercial mouse non-purified diet (Harlan, Indianapolis,
IN) ad libitum. Mice were maintained for 15 weeks on a semi-
purified defined diet that was adequate in all nutrients, containing
320 (g/kg diet) sucrose, 200 casein, 220 corn starch, 3 DL-
methionine, 35 AIN 76 salt mix, 10 AIN 76 mineral mix, 2 choline
chloride, 60 cellulose (Bio-Serv, Frenchtown, NJ), 150 corn oil
(CO) (Dyets, Bethlehem, PA) or 115 vacuum-deodorized Menha-
den fish oil (FO) (Omega Protein, Houston, TX) plus 35 CO. The
animals were provided the defined diet 2 weeks prior to an
injection of azoxymethane (AOM; 7.5 mg/kg body weight). One
week after the AOM injection, mice were exposed to 3 cycles of
1% dextran sulfate sodium (DSS) for 4 d followed by 17 d of
recovery. Mice were sacrificed 6 weeks after the last DSS
treatment (13 weeks post AOM injection) by CO2 asphyxiation.
Colon lesions were mapped and excised prior to colonic mucosa
isolation by scraping, and the mucosa was snap frozen in liquid
nitrogen and stored at -80uC until homogenization. Lesions were
fixed in 4% paraformaldehyde, embedded in paraffin, stained with
hematoxylin-eosin, and evaluated in a blinded manner by a board-
certified pathologist. For immunoblotting, mucosa was homoge-
nized in ice-cold homogenization buffer as described above. For
immunoprecipitation, mucosa was homogenized using Pierce
ClassicTM IP lysis buffer according to the manufacturer’s
instructions. Following homogenization, lysates were sheared
using a 29G needle, incubated on ice for 30 min, and then
centrifuged at 16,0006g for 20 min. The supernatant was
collected. Protein concentration was determined using Coomassie
Protein Plus assay (Pierce).
Statistics
The effect of 2 independent variables (treatment effects) was
assessed using Student’s t-test. The effect of more than 2
independent variables (treatment effects) was assessed using the
one-way analysis of variance test (ANOVA), and differences
among means were evaluated using Tukey’s post-hoc test of
contrast. P values ,0.05 were considered to be statistically
significant.
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